Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Lantheus (NASDAQ: LNTH ) is a company with a portfolio of pharmaceutical products important for the detection of diseases and cancers. The company has wide margins and double-digit growth, but recently fell 20% after its Q3 2024 report dueMy name is María Fernanda and I am currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, ...